Extending influenza vaccination to individuals aged 50–64: A budget impact analysis

Objectives: Influenza (vernacular name, flu) is a viral infection that causes a high consumption of resources. Several studies have been carried out to provide an economic evaluation of the vaccination programs against influenza. Nevertheless, there is still a lack of evidence about the dynamic effects resulting from the reduction of the transmission power. This study considers the impact on contagiousness of alternative strategies against influenza in people aged 50–64 in Italy, France, Germany, and Spain.Methods: By using the Influsim 2.0 dynamic model, we have determined the social benefits of different coverage levels in every country compared with the ones currently recommended. We have subsequently performed a Budget Impact Analysis to determine whether the currently recommended coverage results from an optimal budget allocation. A probabilistic sensitivity analysis was also conducted.Results: We found that in Germany, the optimal coverage level is 38.5 percent, in France 32.4 percent, in Italy 32.75 percent, and 28.3 percent in Spain. By extending the coverage level, social saving tends to increase up to 100 percent for France and Italy and up to 80 percent for Germany and Spain.Conclusions: Decision makers should allocate the budget for vaccination against influenza consistently with the estimation of the optimal coverage level and with the dynamic effects resulting from the reduction of the transmission power.

Download Full-text

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy

Farmeconomia Health economics and therapeutic pathways ◽

10.7175/fe.v10i1.160 ◽

2009 ◽

Vol 10 (1) ◽

pp. 19-31 ◽

Cited By ~ 1

Author(s):

Maurizio Benucci ◽

Sergio Iannazzo ◽

Luciano Sabadini

Keyword(s):

Rheumatoid Arthritis ◽

Impact Analysis ◽

Budget Impact ◽

Unit Cost ◽

Budget Impact Analysis ◽

Second Line ◽

Number Of Patients ◽

Biologic Dmard ◽

Third Line ◽

The Impact

Objective: a Budget Impact analysis was performed to evaluate cost implications for the Italian National Health Service (NHS) of the introduction of rituximab (RTX) in the treatment of rheumatoid arthritis (RA). Methods: RA patients eligible to treatment with a second-line biologic DMARD (Disease Modifying Antirheumatic Drugs) were identified and quantified and available strategies for their management were explored. Costs associated with the different alternatives were estimated, and the impact on the NHS budget was estimated using a cohort simulation based on a Markov chain with a time horizon of 5 years and 1-year cycles. Seven alternative strategies were analyzed, each of them starting after the failure of a first anti-TNFα: 1) the use of a second and a third anti-TNFα; 2) the use of a second anti-TNFα followed by RTX; 3) the use of a second anti-TNFα followed by abatacept (ABAT); 4) the use of RTX as a second biological line, followed by an anti-TNFα; 5) the use of ABAT as a second biological line, followed by an anti-TNFα; 6) the use of RTX as a second biological line, followed by ABAT; 7) the use of ABAT as a second biological line, followed by RTX. Only direct medical costs were considered: drug acquisition, administration, incidental premedication and monitoring exams. Results: Italian patients eligible to second biological line therapies (RA patients refractory or intolerant to at least one anti-TNFα therapy) were estimated in about 650 per year. The adoption of RTX as a second line therapy produced a substantial saving in total costs (-33% at the fifth year) with respect to the strategy with RTX as third line and the one with only anti-TNFα (the last two resulting substantially cost-equivalent). The number of patients in active treatment (biologic DMARD) per unit cost resulted of about 8.1 patient-years/100,000 € with the strategy based only on anti-TNFα and increased of 10% with RTX as a third line. The strategy of RTX as a second line provided a further 41% increase (with respect to RTX as a third line). Conclusions: the introduction of RTX in the treatment of Italian RA patients represents a valuable new therapeutic option for this population especially if anticipated after a first anti-TNFα failure; it can also induce a reduction in health resources consumption for the NHS.

Download Full-text

Sa1429 THE IMPACT OF ENDOSCOPIC ULTRASOUND GUIDED GALLBLADDER DRAINAGE (EUS-GBD) ON REDUCING COSTS OF REINTERVENTION AND UNPLANNED READMISSION: A BUDGET IMPACT ANALYSIS

Gastrointestinal Endoscopy ◽

10.1016/j.gie.2020.03.1225 ◽

2020 ◽

Vol 91 (6) ◽

pp. AB185

Author(s):

Shannon M. Chan ◽

Marc Chong ◽

Jeremy Y. Teoh ◽

Hon Chi Yip ◽

Philip Wai Yan W. Chiu ◽

...

Keyword(s):

Endoscopic Ultrasound ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Unplanned Readmission ◽

Ultrasound Guided ◽

Gallbladder Drainage ◽

Reducing Costs ◽

The Impact

Download Full-text

Abstract T P210: Budget Impact Analysis (BIA) of Telestroke in the Pacific Northwest

Stroke ◽

10.1161/str.46.suppl_1.tp210 ◽

2015 ◽

Vol 46 (suppl_1) ◽

Author(s):

Richard Nelson ◽

Alexandra Lesko ◽

Jennifer Majersik ◽

Nicholas Okon ◽

Elizabeth Baraban

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Skilled Nursing Facility ◽

Budget Impact Analysis ◽

System Level ◽

Decision Analytic Model ◽

Bottom Line ◽

Patient Level ◽

Implementation Costs ◽

The Impact

Background: Assessed from the budget holder’s perspective over a short-term time horizon, a budget impact analysis (BIA) is an economic assessment that estimates the financial consequences on local budgets of adopting a new intervention. To date, BIA has not been published specific to telestroke. Objective: We conducted a BIA of a telestroke network using patient- and system-level data from the Providence Telestroke Network (PTN) to assess overall financial impact. Methods: We modeled the care of a patient with acute ischemic stroke (AIS) presenting to a spoke hospital. Patient-level inputs (IV tPA usage; spoke admission vs. transfer to hub; mortality; and discharge to a rehab facility, skilled nursing facility, or home) were used to populate a decision analytic model from before and after telestroke implementation. We used patient-level cost data by NIHSS to obtain mean costs by patient type, and modeled cost per patient from spoke and hub perspectives, if the spoke hospital was or was not part of PTN. We used the mean number of AIS patients seen at PTN spokes per year (n=14.4) and the number of PTN spokes (n=17) to generate the budget impact of telestroke on the individual spoke, all spokes combined, and the hub. Results: BIA results are presented in Table 1 by time period (12, 24, and 36 months) and proportions of telestroke implementation costs paid for by the spoke facility (0%, 50%, and 100%). Conclusions: Our results suggest that telestroke may lead to a decrease in overall cost from the spoke facility perspective even if the spoke facility is responsible for half of the telestroke implementation costs. While complementing prior telestroke cost-effectiveness analyses, the results from this BIA can assist decision makers at community hospitals who are considering joining a telestroke network by demonstrating the impact that it would have on the hospital’s bottom line.

Download Full-text